Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting
Dateline City:
WHITEHOUSE STATION, N.J.
Interim results of C-SWIFT, a Phase 2 study evaluating ultra-short treatment durations of grazoprevir/elbasvir (MK-5172/MK-8742) plus sofosbuvir, to be presented
Results from the C-WORTHy study, a Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742) across multiple patient populations, including difficult-to-cure, to be presented
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data from clinical studies of the company’s
investigational, oral, once-daily, fixed-dose combination chronic
hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are
scheduled to be presented at the 65th American Association
for the Study of Liver Diseases (AASLD) Annual Meeting, also known as
The Liver Meeting®. The meeting is scheduled to take place at
the John B.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088
Ticker Slug:
...
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Clinical Trials | Hepatitis | Hepatitis C | Liver | Liver Disease | Merck | Pharmaceuticals | Study | Urology & Nephrology